SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety Overall response rate for iSCIB1+ was 69% for target HLA type ...

Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a leading clinical-stage company ...

By sparking the immune system into action, radiation therapy makes certain tumors that resist immunotherapy susceptible to ...

Scancell has linked iSCIB1+ to a 69% response rate in advanced melanoma, lead | Scancell has linked iSCIB1+ to a 69% response ...

BMO Capital Markets pointed to FDA leadership, and CBER Director Vinay Prasad in particular, as potential factors in the ...

By sparking the immune system into action, radiation therapy makes certain tumors that resist immunotherapy susceptible to ...

SCOPE is testing administration of intramuscular SCIB1 and intradermal iSCIB1+, which codes for various melanoma antigens ...

Our research, if it is successful, then we will develop a new immunotherapy, so the next step will be a clinical trial,” said MSU professor Dohun Pyeon.

The Company recently published a proof-of-concept study in Frontiers in Pharmacology, demonstrating that therapeutic IgG1 ...

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...

Vusolimogene oderparepvec is a genetically modified herpes simplex type 1 virus designed to directly destroy tumors and generate an anti-tumor immune response.

Vicebio Ltd, a biopharmaceutical company developing novel vaccines, has entered an exclusive, definitive agreement to be ...